The University of Pittsburgh’s Center for Vaccine Research is in the process of obtaining samples of the novel coronavirus from the U.S. Centers for Disease Control and Prevention in hopes of developing interventions including a vaccine, officials said Wednesday.
Paul Duprex, director of the center, briefed faculty leaders mid-afternoon on the Oakland campus about the center’s plans, its interest in working with U.S. and world health experts to study the virus as well as the logistics of safely bringing the virus samples to the city and campus.
Mr. Duprex could not say exactly when the center expects to receive the virus. He said it will be transported by air and ground using approved shippers experienced in safely transporting biological and infectious materials.
Pitt’s Center for Vaccine Research is one of the few laboratories nationwide designed to be able to handle pathogens of concern, Pitt officials said.
The center is pursuing funding to potentially develop a vaccine for COVID-19, the new name given the virus by the World Health Organization, which has killed more than 1,100 people, nearly all of them in mainland China.
Mr. Duprex said there is a tradition in Pittsburgh of working on disease interventions dating back to the polio crisis and the late Dr. Jonas Salk.
Read More
“We have the experience. We have the facilities within the center for vaccine research,” he said. “There has been significant investments from the university and our school of medicine over many years to build and support those facilities.”
There are almost 45,000 cases of the deadly disease, nearly all of them in mainland China, centered in Hubei Province. The death toll early this week eclipsed that of the SARS virus in the early 2000s.
Mr. Duprex appeared in Posvar Hall at a regular University Senate meeting. His remarks were added to the 3 p.m. meeting shortly before it began, and he took reporters questions afterward at an impromptu news conference.
It was not clear from Pitt officials how many other institutions have received or are preparing to receive virus samples.
A spokesman for the Centers for Disease Control and Prevention in Atlanta could not immediately be reached for comment.
The speed with which people move from country to country, including air travel, exacerbates the virus’ ability to spread as it obtains hosts. However, Mr. Duprex said significant efforts to quarantine and control movement have helped keep cases in countries like the U.S. relatively small so far, at 13.
Pitt is one among a number of entities here and elsewhere interested in working toward a way to combat the virus’ spread.
“We need to understand where the virus is. We need to work on it. Grow it, understand [it],” he said.
The Center for Vaccine Research is located in Biomedical Science Tower 3 (BST3) on Pitt’s campus, near UPMC-Presbyterian Hospital. Its mission centers on “development of diagnostics, therapeutics and vaccines for infectious agents,” according to its web site.
The center employs work of scientists from an array of disciplines in infectious disease research and is expanding its footprint in vaccine research and development, according to Pitt. The center supports work elsewhere at the university and UPMC on emerging infections.
Facilities it has access to include the Regional Biocontainment Laboratory designed to assist researchers and the national biodefense network through a state-of-the-art Biosafety Level 3 (BSL-3) and Animal Biosafety Level 3 (ABSL-3) laboratories, according to information on Pitt’s web site.
Polio killed or paralyzed more than half a million people a year worldwide during the 1940s and 1950s, when its impact peaked. Some who became sick were unable to breathe on their own. Pitt recruited Dr. Salk in the 1940s, and efforts by a research team he assembled, and a vast national controlled trial, led to a government-approved vaccine in 1955.
A World Health Organization forum Tuesday and Wednesday in Geneva, Switzerland, was expected to yield a global research agenda for the virus and help fast-track “development and evaluation of effective diagnostic tests, vaccines and medicines, while establishing mechanisms for affordable access to vulnerable populations,” according to a statement by the organization.
Mr. Duprex said Pitt and the center are a small cog in a much larger wheel of expertise fighting the virus.
“We will play our part because we have no choice,” he said. “We have been resourced. We have this mandate to work on emerging diseases. We have the knowledge.”
Bill Schackner: bschackner@post-gazette. com, 412-263-1977 and on Twitter: @Bschackner






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.